TGNA
53
2
UPS
41
-4
DG
2
-6
JWN
40
-2
MTCH
37
7
ACN
47
-2
BIIB
26
2
EQIX
60
-2
DHI
48
3
URBN
38
-4
ETR
68
3
SO
55
-2
TRV
53
-3
TAP
58
-2
AKAM
43
3
ILMN
32
-3
HCP
58
4
SRE
63
-3
FDX
36
-4
CVS
48
3
TGNA
53
2
UPS
41
-4
DG
2
-6
JWN
40
-2
MTCH
37
7
ACN
47
-2
BIIB
26
2
EQIX
60
-2
DHI
48
3
URBN
38
-4
ETR
68
3
SO
55
-2
TRV
53
-3
TAP
58
-2
AKAM
43
3
ILMN
32
-3
HCP
58
4
SRE
63
-3
FDX
36
-4
CVS
48
3
Financhill
Back

Perspective Therapeutics 10K Form

Sell
30

CATX
Perspective Therapeutics

Last Price:
3.99
Seasonality Move:
40.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CATX News And Ratings

See the #1 stock for the next 7 days that we like better than CATX

CATX Financial Statistics

Sales & Book Value

Annual Sales: $3.55M
Cash Flow: $-26.35M
Price / Cash Flow: 0
Annual Sales: $4.86
Price / Book: 1.43

Profitability

EPS (TTM): -1.46000
Net Income (TTM): $-63.79M
Gross Margin: $817K
Return on Equity: 0%
Return on Assets: 0%

Perspective Therapeutics Earnings Forecast

Key Perspective Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for CATX is 23.00%.
  • The Selling, General & Administrative Expenses for CATX have been equal to 200.08% of Gross Profit Margin.
  • The Interest Expense is -0.18% of Operating Income.
  • Per Share Earnings over the last 30 years have been positive in 16 years.

Perspective Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CATX
Website: perspectivetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CATX Technical Analysis vs Fundamental Analysis

Sell
30
Perspective Therapeutics (CATX) is a Sell

Is Perspective Therapeutics a Buy or a Sell?